Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke.
The use of tissue plasminogen activator (tPA) as a thrombolytic treatment in ischemic stroke is limited largely due to concerns for hemorrhagic complications. The underlying mechanisms are still unknown, but evidence is beginning to emerge that tPA interacts with key regulators of the neurovascular unit (NVU), and that these interactions may contribute to the undesirable side effects associated with the use of tPA in ischemic stroke. Understanding these connections and tPA's normal function within the NVU may offer new insights into future therapeutic approaches.
Su
E J
EJ
Department of Internal Medicine, University of Michigan Medical School, MI 48109, USA.
Fredriksson
L
L
Schielke
G P
GP
Eriksson
U
U
Lawrence
D A
DA
D001808:Blood Vessels / Q000294:innervation; D002560:Cerebrovascular Circulation; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D015398:Signal Transduction; D020521:Stroke / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000494:pharmacology* / Q000627:therapeutic use
D010982:Platelet-Derived Growth Factor; D010959:Tissue Plasminogen Activator